Conceptus® to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
2009-11-04 14:52:05 -
Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that Mark Sieczkarek, president and chief executive officer, will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009, at 2:10 p.m.
ET. The conference will be held at the St. Regis Hotel in New
York City.
A live webcast of the presentation will be available by going to www.conceptus.com :
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.
About the Essure
® Procedure
The Essure
® procedure is a permanent birth control method that can be done in the comfort of a physician’s office in about 13 minutes (average hysteroscopic procedure time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Small, flexible micro-inserts are placed in the woman’s fallopian tubes through the cervix without incisions.
Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.8 percent effective (based on four years of follow-up) with zero pregnancies reported in clinical trials.
Three months after the Essure procedure, a doctor performs an Essure Confirmation Test to confirm that the fallopian tubes are fully blocked and that the patient can rely on Essure for permanent birth control with full confidence. Essure was FDA-approved in 2002 and more than 340,000 women worldwide have undergone the Essure procedure.
Essure and Conceptus
® are registered trademarks of Conceptus Inc.
About Conceptus, Inc.
Conceptus, Inc. (NASDAQ: CPTS), is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Mountain View, Calif.-based company manufactures and markets Essure permanent birth control. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.
Please visit www.essure.com :
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area. Information about Conceptus is available at www.conceptus.com :
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
©2009. All rights reserved. Conceptus and Essure are registered trademarks and your Family is Complete your Choice is Clear is a service mark of Conceptus Inc.
CorporateConceptusGregory
Lichtwardt, CFO650-962-4039
glichtwardt@conceptus.com : mailto:glichtwardt@conceptus.com orInvestor
RelationsLippert/Heilshorn &
AssociatesKim Sutton Golodetz212-838-3777
kgolodetz@lhai.com : mailto:kgolodetz@lhai.com orBruce
Voss310-691-7100
bvoss@lhai.com : mailto:bvoss@lhai.com orMediaConceptusPublic
Relations650-962-4126
publicrelations@conceptus.com : mailto:publicrelations@conceptus.com
